Document Detail


Long-term follow-up of co-administration of diltiazem and cyclosporine in Chinese kidney transplant recipients.
MedLine Citation:
PMID:  20370446     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Co-administration of diltiazem and cyclosporine A (CsA) in kidney transplant recipients shows improvement of renal transplantation outcomes. METHODS: We respectively analyzed 1531 kidney transplant recipients treated by different immunosuppressive therapy schemes from 1986 to 2003. They were divided into three groups depending on their immunosuppressive therapy schemes: control group with a standard triple therapy without use of diltiazem; study group I with the combination of diltiazem and the standard triple therapy but slightly low CsA; study group II with combination of diltiazem and a modified standard triple therapy but lower CsA. The CsA blood concentrations, posttransplant complications, and long-term survival in the three groups were compared. RESULTS: The results showed that the patient and allograft survival in the study group II was 69.9 and 65.1%, respectively, significantly higher than that in the control group (50.7 and 47.6%). Occurrence of hepatotoxicity and nephrotoxicity episodes was higher in the control group than those in the study group I and the study group II. The incidence of acute rejection in the control group was 30.3% (23/76), similar to 28.0% (184/657) in study group I, but statistically significantly higher than 7.6% (61/798) in the study group II. CONCLUSION: Combination of diltiazem and CsA in the kidney allograft recipients tends to reduce the CsA oral dosage, improve patient survival, and decrease the occurrence of hepatotoxicity and nephrotoxicity.
Authors:
Wujun Xue; Xiaoming Ding; Puxun Tian; Xiaoming Pan; Hang Yan; Jun Hou; Xinshun Feng; Heli Xiang; Xiaohui Tian
Related Documents :
2305466 - The role of cold ischemia in a provincial organ-sharing program in the cyclosporine era.
2643236 - Sequential antilymphocyte globulin/cyclosporine immunosuppression in cadaveric renal tr...
9587046 - Relationship between area under the concentration versus time curve of cyclosporin a, c...
20150906 - Maintenance immunosuppressive therapy and generic cyclosporine a use in adult renal tra...
8453356 - Interleukin-2 in autologous bone marrow transplantation.
20056756 - Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ tra...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Renal failure     Volume:  32     ISSN:  1525-6049     ISO Abbreviation:  Ren Fail     Publication Date:  2010 Jan 
Date Detail:
Created Date:  2010-04-07     Completed Date:  2010-07-20     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8701128     Medline TA:  Ren Fail     Country:  England    
Other Details:
Languages:  eng     Pagination:  314-9     Citation Subset:  IM    
Affiliation:
Kidney Transplantation Center, The First Affiliated Hospital, School of Medicine, Xi'an Jiaotong University, Xi'an, Shaanxi, China. xw5886@pub.xaonline.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Oral
Adult
Calcium Channel Blockers / administration & dosage*
Cyclosporine / administration & dosage*,  adverse effects,  pharmacokinetics
Diltiazem / administration & dosage*
Drug Therapy, Combination
Female
Graft Survival
Humans
Immunosuppressive Agents / administration & dosage*,  adverse effects,  pharmacokinetics
Kidney Transplantation / mortality
Male
Survival Rate
Chemical
Reg. No./Substance:
0/Calcium Channel Blockers; 0/Immunosuppressive Agents; 42399-41-7/Diltiazem; 59865-13-3/Cyclosporine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Acute kidney injury in late pregnancy in developing countries.
Next Document:  Enoxaparin versus unfractioned heparin as anticoagulant for continuous venovenous hemodialysis: a ra...